Drug Shortage Report for TEVA-LANSOPRAZOLE

Last updated on 2023-07-05 History
Report ID 144747
Drug Identification Number 02280523
Brand name TEVA-LANSOPRAZOLE
Common or Proper name TEVA-LANSOPRAZOLE
Company Name TEVA CANADA LIMITED
Market Status MARKETED
Active Ingredient(s) LANSOPRAZOLE
Strength(s) 30MG
Dosage form(s) CAPSULE (DELAYED RELEASE)
Route of administration ORAL ORAL
Packaging sizes (GTIN)

Click here to see a list of all reports for this drug.

(See additional packaging sizes)
Additional packaging sizes 100, 500
ATC code A02BC
ATC description DRUGS FOR PEPTIC ULCER AND GASTROESOPHAGEAL REFLUX DISEASE (GERD)
Reason for shortage Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2021-08-30
Estimated end date 2023-07-10
Actual end date 2023-07-04
Shortage status Resolved
Updated date 2023-07-05
Company comments
Health Canada comments
Tier 3 Status No
Contact Address 30 NOVOPHARM COURT
TORONTO, ONTARIO
CANADA M1B 2K9
Company contact information

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v23 2022-12-01 French Compare
v22 2022-12-01 English Compare
v21 2022-10-28 French Compare
v20 2022-10-28 English Compare
v19 2022-09-22 French Compare
v18 2022-09-22 English Compare
v17 2022-09-22 French Compare
v16 2022-09-22 English Compare
v15 2022-09-07 French Compare
v14 2022-09-07 English Compare
v13 2022-06-30 French Compare
v12 2022-06-30 English Compare
v11 2022-03-17 French Compare
v10 2022-03-17 English Compare
v9 2022-01-20 French Compare
v8 2022-01-20 English Compare
v7 2021-12-08 French Compare
v6 2021-12-08 English Compare
v5 2021-10-07 French Compare
v4 2021-10-07 English Compare

Showing 21 to 40 of 43